MX2022000069A - Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. - Google Patents
Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.Info
- Publication number
- MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A
- Authority
- MX
- Mexico
- Prior art keywords
- oxobutan
- diazaspiro
- octane
- oxo
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865826P | 2019-06-24 | 2019-06-24 | |
| PCT/US2020/039163 WO2020263847A1 (en) | 2019-06-24 | 2020-06-23 | Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000069A true MX2022000069A (es) | 2022-05-24 |
Family
ID=74060350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000069A MX2022000069A (es) | 2019-06-24 | 2020-06-23 | Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. |
| MX2025002579A MX2025002579A (es) | 2019-06-24 | 2022-01-03 | Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002579A MX2025002579A (es) | 2019-06-24 | 2022-01-03 | Formas solidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il)-1-oxo-2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y metodos para prepararlas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220267341A1 (enExample) |
| EP (1) | EP3986399A4 (enExample) |
| JP (2) | JP7617043B2 (enExample) |
| CN (1) | CN114364380A (enExample) |
| AU (1) | AU2020304001B2 (enExample) |
| BR (1) | BR112021026380A2 (enExample) |
| CA (1) | CA3144600A1 (enExample) |
| IL (1) | IL289198A (enExample) |
| MA (1) | MA56550A (enExample) |
| MX (2) | MX2022000069A (enExample) |
| WO (1) | WO2020263847A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4484431A3 (en) * | 2019-06-24 | 2025-03-26 | Naurex Inc. | Processes and intermediates for producing diazaspiro lactam compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323204D0 (en) * | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| BRPI0918868B8 (pt) * | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| US9758525B2 (en) * | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| PE20151416A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| DK3436463T3 (da) * | 2016-03-28 | 2021-08-30 | Takeda Pharmaceuticals Co | Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| EP4484431A3 (en) * | 2019-06-24 | 2025-03-26 | Naurex Inc. | Processes and intermediates for producing diazaspiro lactam compounds |
-
2020
- 2020-06-23 US US17/621,907 patent/US20220267341A1/en active Pending
- 2020-06-23 EP EP20832010.1A patent/EP3986399A4/en active Pending
- 2020-06-23 CN CN202080059974.0A patent/CN114364380A/zh active Pending
- 2020-06-23 BR BR112021026380A patent/BR112021026380A2/pt unknown
- 2020-06-23 JP JP2021576883A patent/JP7617043B2/ja active Active
- 2020-06-23 MA MA056550A patent/MA56550A/fr unknown
- 2020-06-23 CA CA3144600A patent/CA3144600A1/en active Pending
- 2020-06-23 MX MX2022000069A patent/MX2022000069A/es unknown
- 2020-06-23 AU AU2020304001A patent/AU2020304001B2/en active Active
- 2020-06-23 WO PCT/US2020/039163 patent/WO2020263847A1/en not_active Ceased
-
2021
- 2021-12-21 IL IL289198A patent/IL289198A/en unknown
-
2022
- 2022-01-03 MX MX2025002579A patent/MX2025002579A/es unknown
-
2025
- 2025-01-06 JP JP2025001914A patent/JP2025069143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020263847A1 (en) | 2020-12-30 |
| AU2020304001B2 (en) | 2026-04-09 |
| JP2025069143A (ja) | 2025-04-30 |
| MA56550A (fr) | 2022-04-27 |
| US20220267341A1 (en) | 2022-08-25 |
| KR20220061088A (ko) | 2022-05-12 |
| CA3144600A1 (en) | 2020-12-30 |
| EP3986399A4 (en) | 2023-06-07 |
| JP7617043B2 (ja) | 2025-01-17 |
| JP2022539342A (ja) | 2022-09-08 |
| IL289198A (en) | 2022-02-01 |
| AU2020304001A1 (en) | 2022-01-27 |
| CN114364380A (zh) | 2022-04-15 |
| MX2025002579A (es) | 2025-04-02 |
| BR112021026380A2 (pt) | 2022-05-10 |
| EP3986399A1 (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4512399A3 (en) | Solid state forms of tafamidis and salts thereof | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| MA40236A (fr) | Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide | |
| CL2012002355A1 (es) | Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih. | |
| MX2019004611A (es) | Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas. | |
| BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
| NZ721952A (en) | Delayed release compositions of linaclotide | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| BR112018071831A2 (pt) | composições anti-irritantes sinérgicas de taurina e aloé e métodos | |
| JOP20210004A1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| EP4327880A3 (en) | Solid state form of ribociclib succinate | |
| UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
| EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
| MX382609B (es) | Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. | |
| WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| ZA202005325B (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду |